Trimethoprim/sulfamethoxazole versus vancomycin in the treatment of healthcare/ventilator-associated MRSA pneumonia: a case–control study

March 11, 2017 at 7:03 pm

Journal of Antimicrobial Chemotherapy March 2017 V.72 N.3 P.882-887

EDITOR’S CHOICE

Noa Eliakim-Raz  Moran Hellerman  Dafna Yahav  Jonathan Cohen  Ili Margalit Sharon Fisher  Oren Zusman  Hila Shaked  Jihad Bishara

Objectives:

Therapeutic options available to treat MRSA pneumonia are limited. Trimethoprim/sulfamethoxazole is an attractive treatment because of its bactericidal anti-MRSA activity, oral and parenteral formulations and good penetration to the lung tissue. We aimed to compare the efficacy and safety of trimethoprim/sulfamethoxazole with vancomycin in the treatment of healthcare/ventilator-associated MRSA pneumonia.

Methods:

We carried out a retrospective case–control study of all consecutive hospitalized adult patients diagnosed with MRSA pneumonia at Beilinson Hospital during 2010–15 and treated with either vancomycin or trimethoprim/sulfamethoxazole. The primary outcomes were all-cause mortality at 30 days and clinical failure at the end of treatment. In order to reduce bias affecting the decision to use a specific antibiotic and as a sensitivity analysis, a propensity-score model for choosing between vancomycin and trimethoprim/sulfamethoxazole was used.

Results:

We identified 42 patients with MRSA pneumonia treated with trimethoprim/sulfamethoxazole and 39 treated with vancomycin. There were no significant differences in the baseline characteristics between the groups. Vancomycin-treated patients showed significantly higher 30 day mortality on both multivariate analysis (HR = 5.28; 95% CI = 1.50–18.60; P < 0.05) and sensitivity analysis with propensity score [vancomycin 13/24 (54.1%) versus trimethoprim/sulfamethoxazole 4/24 (16.7%); P < 0.05], and higher clinical failure rates [vancomycin 23/39 (59%) versus trimethoprim/sulfamethoxazole 15/42 (35.7%); P < 0.05], also in the sensitivity analysis with propensity score [vancomycin 14/24 (58.3%) versus trimethoprim/sulfamethoxazole 6/24 (25%); P < 0.05]. The rates of side effects in both arms were comparable.

Conclusions:

Trimethoprim/sulfamethoxazole appears to be superior to vancomycin in the treatment of MRSA pneumonia. A large-scale randomized controlled trial is needed to evaluate these findings.

PDF

https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/72/3/10.1093_jac_dkw510/1/dkw510.pdf?Expires=1489615014&Signature=GUbYAAMUI1ZQdilG1U3OM6P~3WSjcorbq916JZ78Cr2SGmVr5wciTL9rNEEhjIOTj5DCoArfSpUgOq7uvJQ65fKLpDrWs0xIn3PAkYe7K9hmh73z7J~DUWQGA2UwOJiY5S8JsOaflL3Hnzey68EhpfIoBB6q-3CfiSt-C0g1XTY2uTRmN3xAE1z0nDX-Od2UGgbKWUHgslxYUwzZ7Vy2fyrcNIv1wIVa3MuggHAzT8M3WZ2NtRMhbYCsrrzCDIJawqd80SAmMo5gRGPLdXuX4oM0iTQLrRDaRVe0l3H7KEDIWwExiYgWokACmTdmIHapOAeL102wozydA194MFvOeA__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q

Advertisements

Entry filed under: Antimicrobianos, Bacterias, Bacteriemias, Epidemiología, Health Care-Associated Infections, Infecciones nosocomiales, Infecciones respiratorias, Metodos diagnosticos, Resistencia bacteriana, Sepsis, Update.

Antibiotic prescribing in patients with self-reported sore throat Recurrent furunculosis – challenges and management: a review.


Calendar

March 2017
M T W T F S S
« Feb   Apr »
 12345
6789101112
13141516171819
20212223242526
2728293031  

Most Recent Posts


%d bloggers like this: